Browse News
Filter News
Found 210 articles
-
Researchers and drug developers have searched for a way to deliver IL-12 to patients. Researchers at the University of Chicago’s Pritzker School of Molecular Engineering may have found one.
-
Pregnant Women Produce Super Antibodies to Protect Newborns, Now Scientists Know How
6/8/2022
Scientists discovered years ago that newborn infants depend upon immune components transferred from their mothers to survive the onslaught of pathogens that begin invading their bodies as soon as they are born.
-
Janux Therapeutics Announces FDA Clearance of Investigational New Drug Application for JANX007, a PSMA-TRACTr for Metastatic Castration-Resistant Prostate Cancer
5/31/2022
Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s investigational new drug (IND) application for its lead product candidate, JANX007.
-
CytomX Therapeutics Announces First Patient Dosed with CX-904 in Phase 1 Study in Patients with Advanced Solid Tumors- EGFRxCD3-targeting bispecific is sixth CytomX Probody® therapeutic candidate to enter the clinic -
5/26/2022
CytomX Therapeutics, Inc. today announced that the first patient has been dosed in a Phase 1 dose-escalation study of CX-904 ( NCT05387265 ).
-
Researchers at Hokkaido University in Japan, in a collaboration with American scientists, may have unlocked the mechanism that drives widespread inflammation in inflammatory diseases.
-
Janux Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights
5/10/2022
Janux Therapeutics, Inc., a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager and Tumor Activated Immunomodulator platforms, reported financial results for the first quarter ended March 31, 2022 and provided a business update.
-
Janux Therapeutics to Present Preclinical Data at the 18th Annual PEGS Boston for PSMA-TRACTr and EGFR-TRACTr
4/26/2022
Janux Therapeutics today announced its upcoming presentation of preclinical data for the Company’s two lead TRACTr programs, PSMA-TRACTr (JANX007) and EGFR-TRACTr (JANX008).
-
LumiThera Announces US LIGHTSITE III Clinical Trial Meets Primary Efficacy Endpoint in Improving Vision in Dry Age-Related Macular Degeneration Subjects
3/22/2022
LumiThera Inc. announced positive findings in its LIGHTSITE III, multi-center clinical trial in non-neovascular Age-Related Macular Degeneration subjects treated with the Valeda® Light Delivery System.
-
New Data Further Reinforce Efficacy Of Tezspire™ (Tezepelumab-Ekko) In A Broad Population Of Severe Asthma Patients
2/26/2022
Amgen announced results from a pooled post-hoc analysis of the pivotal NAVIGATOR Phase 3 and PATHWAY Phase 2b trials showed TEZSPIRE™ demonstrated reductions in the annualized asthma exacerbation rate across biomarker subgroups of patients with severe asthma.
-
Werewolf Therapeutics is designing and developing molecules that unleash the natural ferocity of cytokines for the treatment of cancer.
-
TEZSPIRE™ (TEZEPELUMAB-EKKO) NOW AVAILABLE IN THE UNITED STATES FOR THE TREATMENT OF SEVERE ASTHMA
1/13/2022
Amgen (NASDAQ:AMGN) and AstraZeneca today announced TEZSPIRE™ (tezepelumab-ekko) is now available for shipment to wholesalers in the U.S. TEZSPIRE was approved by the U.S. Food and Drug Administration (FDA) on Dec. 17, 2021 for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma.
-
TEZSPIRE Now Available in the United States for the Treatment of Severe Asthma
1/13/2022
AstraZeneca and Amgen today announced TEZSPIRE™ (tezepelumab-ekko) is now available for shipment to wholesalers in the US.
-
CytomX Therapeutics Announces Preliminary Results for Ongoing Phase 2 Expansion Study of CX-2029, a First-in-Class Antibody-Drug Conjugate Candidate Targeting the Transferrin Receptor, CD71
12/20/2021
CytomX Therapeutics, Inc. (Nasdaq: CTMX), today announced preliminary Phase 2 results in patients with either advanced squamous non-small cell lung cancer (sqNSCLC) or head and neck squamous cell carcinoma (HNSCC), who were treated with CX-2029 – a CD71-directed conditionally activated antibody-drug conjugate (ADC) being co-developed by CytomX and AbbVie.
-
FDA APPROVES TEZSPIRE™ (TEZEPELUMAB-EKKO) IN THE U.S. FOR SEVERE ASTHMA
12/17/2021
Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Amgen and AstraZeneca's Tezspire™ (tezepelumab-ekko) for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma.
-
TEZSPIRE (tezepelumab) Approved in the US for Severe Asthma
12/17/2021
AstraZeneca and Amgen’s TEZSPIRE (tezepelumab-ekko) has been approved in the US for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma.
-
KAHR to Host Key Opinion Leader Webinar on the Potential of CD47 Therapeutics for the Treatment of Solid Tumor and Hematologic Malignancies
11/23/2021
KAHR, a cancer immunotherapy company developing novel multifunctional immune-recruitment proteins, today announced it will host a virtual key opinion leader (KOL) webinar on the potential of CD47 therapeutics for the treatment of solid tumor and hematologic malignancies on Thursday, December 2, 2021, from 4:30 pm to 5:30 pm ET.
-
Clinical Catch-Up: October 11-15
10/18/2021
It was yet another busy week for clinical trial announcements. Take a look. -
Ascendis Pharma A/S Announces U.S. Commercial Launch of SKYTROFA® (Lonapegsomatropin-tcgd), the First and Only FDA Approved Once-Weekly Treatment for Pediatric Growth Hormone Deficiency
10/15/2021
Ascendis Pharma A/S (Nasdaq: ASND), today announced the U.S. commercial launch of SKYTROFA (lonapegsomatropin-tcgd), its once-weekly treatment for the treatment of pediatric patients one year and older who weigh at least 11.5 kg (25.4 lb) and have growth failure due to inadequate secretion of endogenous growth hormone (GH).
-
Adverum Presents Clinical Data on ADVM-022 at the American Society of Retina Specialists 39th Annual Scientific Meeting
10/9/2021
Adverum Biotechnologies, Inc. is presenting data from the INFINITY clinical trial of ADVM-022 in patients with diabetic macular edema during the American Society of Retina Specialists 39th Annual Scientific Meeting and will be presenting an encore presentation of long-term data from the OPTIC trial of ADVM-022 for wet AMD on Monday, October 11, 2021 at 8:50 am CT.
-
Amunix Presents Preclinical Data on Its XPAT T Cell Engager Platform at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics
10/7/2021
Amunix Pharmaceuticals, Inc. (Amunix), today announced that preclinical data from its lead program, AMX-818 (HER2-XPAT), were presented at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics.